Targeted delivery of interferon-α to hepatitis B virus-infected cells using T-cell receptor-like antibodies

Changhua Ji, Seetharama S. Konduru, Georg Tiefenthaler, Jennifer Cano, Tenny Tang, Zi Zong Ho, Denise Teoh, Sandhya Bohini, Antony Chen, Surya Sankuratri, Paul A. Macary, Patrick Kennedy, Han Ma, Stefan Ries, Klaus Klumpp, Erhard Kopetzki, Antonio Bertoletti

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

During antiviral therapy, specific delivery of interferon-α (IFNα) to infected cells may increase its antiviral efficacy, trigger a localized immune reaction, and reduce the side effects caused by systemic administration. Two T-cell receptor-like antibodies (TCR-L) able to selectively bind hepatitis B virus (HBV)-infected hepatocytes of chronic hepatitis B patients and recognize core (HBc18-27) and surface (HBs183-91) HBV epitopes associated with different human leukocyte antigen (HLA)-A*02 alleles (A*02:01, A*02:02, A*02:07, A*02:11) were generated. Each antibody was genetically linked to two IFNα molecules to produce TCR-L/IFNα fusion proteins. We demonstrate that the fusion proteins triggered an IFNα response preferentially on the hepatocytes presenting the correct HBV-peptide HLA-complex and that the mechanism of the targeted IFNα response was dependent on the specific binding of the fusion proteins to the HLA/HBV peptide complexes through the TCR-like variable regions of the antibodies. Conclusion: TCR-L antibodies can be used to target cytokines to HBV-infected hepatocytes in vitro. Fusion of IFNα to TCR-L decreased the intrinsic biological activity of IFNα but preserved the overall specificity of the protein for the cognate HBV peptide/HLA complexes. This induction of an effective IFNα response selectively in HBV-infected cells might have a therapeutic advantage in comparison to the currently used native or pegylated IFNα.

Original languageEnglish
Pages (from-to)2027-2038
Number of pages12
JournalHepatology
Volume56
Issue number6
DOIs
Publication statusPublished - Dec 2012
Externally publishedYes

Fingerprint

T-Cell Antigen Receptor
Hepatitis B virus
Interferons
Antibodies
HLA Antigens
Hepatocytes
Peptides
Antiviral Agents
Proteins
Chronic Hepatitis B
Epitopes
Carrier Proteins
Alleles
Cytokines
Therapeutics

ASJC Scopus subject areas

  • Hepatology

Cite this

Targeted delivery of interferon-α to hepatitis B virus-infected cells using T-cell receptor-like antibodies. / Ji, Changhua; Konduru, Seetharama S.; Tiefenthaler, Georg; Cano, Jennifer; Tang, Tenny; Ho, Zi Zong; Teoh, Denise; Bohini, Sandhya; Chen, Antony; Sankuratri, Surya; Macary, Paul A.; Kennedy, Patrick; Ma, Han; Ries, Stefan; Klumpp, Klaus; Kopetzki, Erhard; Bertoletti, Antonio.

In: Hepatology, Vol. 56, No. 6, 12.2012, p. 2027-2038.

Research output: Contribution to journalArticle

Ji, C, Konduru, SS, Tiefenthaler, G, Cano, J, Tang, T, Ho, ZZ, Teoh, D, Bohini, S, Chen, A, Sankuratri, S, Macary, PA, Kennedy, P, Ma, H, Ries, S, Klumpp, K, Kopetzki, E & Bertoletti, A 2012, 'Targeted delivery of interferon-α to hepatitis B virus-infected cells using T-cell receptor-like antibodies', Hepatology, vol. 56, no. 6, pp. 2027-2038. https://doi.org/10.1002/hep.25875
Ji, Changhua ; Konduru, Seetharama S. ; Tiefenthaler, Georg ; Cano, Jennifer ; Tang, Tenny ; Ho, Zi Zong ; Teoh, Denise ; Bohini, Sandhya ; Chen, Antony ; Sankuratri, Surya ; Macary, Paul A. ; Kennedy, Patrick ; Ma, Han ; Ries, Stefan ; Klumpp, Klaus ; Kopetzki, Erhard ; Bertoletti, Antonio. / Targeted delivery of interferon-α to hepatitis B virus-infected cells using T-cell receptor-like antibodies. In: Hepatology. 2012 ; Vol. 56, No. 6. pp. 2027-2038.
@article{92cbdc6e2a2f4b8fbb5983799f3602da,
title = "Targeted delivery of interferon-α to hepatitis B virus-infected cells using T-cell receptor-like antibodies",
abstract = "During antiviral therapy, specific delivery of interferon-α (IFNα) to infected cells may increase its antiviral efficacy, trigger a localized immune reaction, and reduce the side effects caused by systemic administration. Two T-cell receptor-like antibodies (TCR-L) able to selectively bind hepatitis B virus (HBV)-infected hepatocytes of chronic hepatitis B patients and recognize core (HBc18-27) and surface (HBs183-91) HBV epitopes associated with different human leukocyte antigen (HLA)-A*02 alleles (A*02:01, A*02:02, A*02:07, A*02:11) were generated. Each antibody was genetically linked to two IFNα molecules to produce TCR-L/IFNα fusion proteins. We demonstrate that the fusion proteins triggered an IFNα response preferentially on the hepatocytes presenting the correct HBV-peptide HLA-complex and that the mechanism of the targeted IFNα response was dependent on the specific binding of the fusion proteins to the HLA/HBV peptide complexes through the TCR-like variable regions of the antibodies. Conclusion: TCR-L antibodies can be used to target cytokines to HBV-infected hepatocytes in vitro. Fusion of IFNα to TCR-L decreased the intrinsic biological activity of IFNα but preserved the overall specificity of the protein for the cognate HBV peptide/HLA complexes. This induction of an effective IFNα response selectively in HBV-infected cells might have a therapeutic advantage in comparison to the currently used native or pegylated IFNα.",
author = "Changhua Ji and Konduru, {Seetharama S.} and Georg Tiefenthaler and Jennifer Cano and Tenny Tang and Ho, {Zi Zong} and Denise Teoh and Sandhya Bohini and Antony Chen and Surya Sankuratri and Macary, {Paul A.} and Patrick Kennedy and Han Ma and Stefan Ries and Klaus Klumpp and Erhard Kopetzki and Antonio Bertoletti",
year = "2012",
month = "12",
doi = "10.1002/hep.25875",
language = "English",
volume = "56",
pages = "2027--2038",
journal = "Hepatology (Baltimore, Md.)",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Targeted delivery of interferon-α to hepatitis B virus-infected cells using T-cell receptor-like antibodies

AU - Ji, Changhua

AU - Konduru, Seetharama S.

AU - Tiefenthaler, Georg

AU - Cano, Jennifer

AU - Tang, Tenny

AU - Ho, Zi Zong

AU - Teoh, Denise

AU - Bohini, Sandhya

AU - Chen, Antony

AU - Sankuratri, Surya

AU - Macary, Paul A.

AU - Kennedy, Patrick

AU - Ma, Han

AU - Ries, Stefan

AU - Klumpp, Klaus

AU - Kopetzki, Erhard

AU - Bertoletti, Antonio

PY - 2012/12

Y1 - 2012/12

N2 - During antiviral therapy, specific delivery of interferon-α (IFNα) to infected cells may increase its antiviral efficacy, trigger a localized immune reaction, and reduce the side effects caused by systemic administration. Two T-cell receptor-like antibodies (TCR-L) able to selectively bind hepatitis B virus (HBV)-infected hepatocytes of chronic hepatitis B patients and recognize core (HBc18-27) and surface (HBs183-91) HBV epitopes associated with different human leukocyte antigen (HLA)-A*02 alleles (A*02:01, A*02:02, A*02:07, A*02:11) were generated. Each antibody was genetically linked to two IFNα molecules to produce TCR-L/IFNα fusion proteins. We demonstrate that the fusion proteins triggered an IFNα response preferentially on the hepatocytes presenting the correct HBV-peptide HLA-complex and that the mechanism of the targeted IFNα response was dependent on the specific binding of the fusion proteins to the HLA/HBV peptide complexes through the TCR-like variable regions of the antibodies. Conclusion: TCR-L antibodies can be used to target cytokines to HBV-infected hepatocytes in vitro. Fusion of IFNα to TCR-L decreased the intrinsic biological activity of IFNα but preserved the overall specificity of the protein for the cognate HBV peptide/HLA complexes. This induction of an effective IFNα response selectively in HBV-infected cells might have a therapeutic advantage in comparison to the currently used native or pegylated IFNα.

AB - During antiviral therapy, specific delivery of interferon-α (IFNα) to infected cells may increase its antiviral efficacy, trigger a localized immune reaction, and reduce the side effects caused by systemic administration. Two T-cell receptor-like antibodies (TCR-L) able to selectively bind hepatitis B virus (HBV)-infected hepatocytes of chronic hepatitis B patients and recognize core (HBc18-27) and surface (HBs183-91) HBV epitopes associated with different human leukocyte antigen (HLA)-A*02 alleles (A*02:01, A*02:02, A*02:07, A*02:11) were generated. Each antibody was genetically linked to two IFNα molecules to produce TCR-L/IFNα fusion proteins. We demonstrate that the fusion proteins triggered an IFNα response preferentially on the hepatocytes presenting the correct HBV-peptide HLA-complex and that the mechanism of the targeted IFNα response was dependent on the specific binding of the fusion proteins to the HLA/HBV peptide complexes through the TCR-like variable regions of the antibodies. Conclusion: TCR-L antibodies can be used to target cytokines to HBV-infected hepatocytes in vitro. Fusion of IFNα to TCR-L decreased the intrinsic biological activity of IFNα but preserved the overall specificity of the protein for the cognate HBV peptide/HLA complexes. This induction of an effective IFNα response selectively in HBV-infected cells might have a therapeutic advantage in comparison to the currently used native or pegylated IFNα.

UR - http://www.scopus.com/inward/record.url?scp=84870539475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870539475&partnerID=8YFLogxK

U2 - 10.1002/hep.25875

DO - 10.1002/hep.25875

M3 - Article

VL - 56

SP - 2027

EP - 2038

JO - Hepatology (Baltimore, Md.)

JF - Hepatology (Baltimore, Md.)

SN - 0270-9139

IS - 6

ER -